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Background: The prevalence of asthma in girls increases after puberty. Previous studies have detected associations
between sex hormones and asthma, as well as between sex hormones and T helper 2 (Th2) asthma-typical immune
responses. Therefore, we hypothesized that exogenous or endogenous sex hormone exposure (represented by oral
contraceptive pill (OCP) use and early menarche, respectively) are associated with DNA methylation (DNA-M) of the
Th2 transcription factor gene, GATA3, in turn affecting the risk of asthma in girls, possibly in interaction with genetic
variants.
Blood samples were collected from 245 female participants aged 18 years randomly selected for methylation
analysis from the Isle of Wight birth cohort, UK. Information on use of OCPs, age at menarche, and concurrent
asthma were assessed by questionnaire. Genome-wide DNA-M was determined using the Illumina Infinium
HumanMethylation450 beadchip. In a first stage, we tested the interaction between sex hormone exposure and
genetic variants on DNA-M of specific cytosine-phosphate-guanine (CpG) sites. In a second stage, we determined
whether these CpG sites interact with genetic variants in GATA3 to explain the risk of asthma.
Results: Interactions between OCP use and seven single nucleotide polymorphisms (SNPs) of GATA3 were analyzed
for 14 CpG sites (stage 1). The interaction between OCP use and SNP rs1269486 was found to be associated with
the methylation level of cg17124583 (P = 0.002, false discovery rate (FDR) adjusted P = 0.04). DNA-M of this same
CpG site was also influenced by the interaction between age at menarche and rs1269486 (P = 0.0017). In stage 2,
we found that cg17124583 modified the association of SNP rs422628 with asthma risk at the age of 18 years
(P = 0.006, FDR adjusted P = 0.04). Subjects with genotype AG showed an increase in average risk ratio (RR) from
0.31 (95% CI: 0.10 to 0.8) to 11.65 (95% CI: 1.71 to 79.5) when methylation level increased from 0.02 to 0.12,
relative to genotype AA.
Conclusion: A two-stage model consisting of genetic variants in the GATA3 gene, OCP use, age at menarche, and
DNA-M may explain how sex hormones in women can increase the asthma prevalence after puberty.
Keywords: GATA3 gene, DNA methylation, genetic variants, epigenetics, oral contraceptives, age at menarche,
asthma, puberty, adolescence, single nucleotide polymorphism, CpG* Correspondence: Karmaus1@memphis.edu
1Division of Epidemiology, Biostatistics, and Environmental Health, School of
Public Health, University of Memphis, Memphis, TN, USA
Full list of author information is available at the end of the article
© 2014 Guthikonda et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Guthikonda et al. Clinical Epigenetics 2014, 6:17 Page 2 of 12
http://www.clinicalepigeneticsjournal.com/content/6/1/17Background
Asthma is a multifactorial disease that is influenced by
the interplay between genetic and environmental factors
[1]. Studies have shown that the asthma prevalence in
girls increases with puberty [1-4]. The mechanism behind
this increase is not yet clear, though we propose that
endocrine effects may be involved. In addition, asthma
and lung function may vary during different phases of the
menstrual cycle, further suggesting a role of sex hormones
in asthma [5-7]. In addition, it has been reported that both
exogenous and endogenous sex hormones influence the
occurrence of asthma in young women [8].
Because estrogen and progesterone are known to de-
crease the contractility of airway smooth muscle, their
positive correlation with asthma is more likely driven by
their effects on the immune system [9]. Specifically, pro-
gesterone stimulates IL-4 production and promotes T
helper 2 (Th2) differentiation [10]. The immunological
effects of estrogen include increased production of TNF-
α by the lungs, increased production of IL-4 by the bone
marrow, and thus migration of eosinophils during aller-
gic inflammation [11]. Furthermore, estrogen decreased
expression of T-regulatory cells [12], increased expres-
sion of IL-5 and IL-13 [13], increased the differentiation
of naive CD4+ cells into Th2 cells [13], and also increased
Th2 responses by augmenting the production of den-
dritic cells [14]. Hence, estrogen and progesterone may
be linked to potential immunological effects and variation
in airway responses.
Oral contraceptive pills (OCPs) are exogenous sex hor-
mone preparations used primarily for birth control, but
also for irregular menstruation, hirsutism, polycystic ovar-
ian disease, and dysmenorrhea. Some studies find a posi-
tive association between OCP use and asthma [15,16],
while other studies find the opposite relationship [17,18],
and yet other studies identified no significant association
[19,20]. In addition, some studies have found early menar-
che to be associated with the risk of adult asthma
[8,15,16], while another study has reported no association
[17,18]. Overall, there is a lack of understanding of
the association between age at menarche, sex hormones,
and asthma.
The transcription factor GATA3, located on chromo-
some 10, encodes a master regulator of Th2 cell differ-
entiation [19] that plays an important role in the
production of cytokines [20,21]. A study by Wada et al,
in a mouse model of asthma, demonstrated increased
production of antigen-induced Th2 cytokines in the
bronchial lymph node cells of female mice compared to
male mice, which was associated with enhanced GATA3
expression [2], suggesting a possible role for sex in regu-
lating the activity of GATA3.
The term epigenetics refers to the changes in pheno-
type or expression of genes that are not due to changesin the sequence of DNA [22]. Epigenetics is considered
to play an important role in regulation and differenti-
ation of T cells and asthma pathogenesis [23,24]. In par-
ticular, DNA methylation (DNA-M) may regulate genes
associated with asthma and allergy [25]. Some single nu-
cleotide polymorphisms (SNPs) can act as methylation
quantitative trait loci (methQTLs) to influence DNA-M
at specific CpG sites, and may be conditional on envir-
onmental exposure [26-28]. To reflect both the genetic
and environmental influences, we call these loci condi-
tional methQTLs.
The role of sex hormones and the potential gender-
related activity of GATA3 in asthma motivated us to
study a possible interaction between oral contraceptives
and GATA3 and further its association with asthma.
Therefore, we hypothesize that exogenous or endogen-
ous sex hormone exposure in interaction with genetic
variants could be associated with DNA-M of GATA3,
which in turn affects the risk of asthma at the age of
18 years. It is also important to understand whether the
change in DNA-M is a cause or a consequence of the
disease. To address this issue we use a two-stage model
proposed by Karmaus et al., which incorporates both
methQTLs and genetic variants [29]. In stage 1, we iden-
tify the conditional methQTLs (influenced by the use of
OCPs) that may result in a change of the DNA-M of spe-
cific CpG sites of the GATA3 gene. These CpG sites differ-
entially methylated depending on OCP use subsequently
may modify the penetrance of certain SNPs, which then
are called modifiable genetic variants (modGVs) [30,31].
In stage 2, we evaluate the interaction of differentially
methylated CpG sites with modGVs on asthma at the age
of 18 years.
Age at menarche is related to changes in endogenous
sex hormones and reflects body changes. In girls, the
earlier the onset of puberty, the longer the exposure to
sex hormones. Hence, we additionally ran our stage 1
model using age at menarche as an alternate indicator of
a possible endocrine effect. Agreement between both ex-
posures would further support our hypothesis.
Results
There were no significant differences in the prevalence
of asthma, BMI, smoking at 18 years, maternal history of
asthma, socioeconomic status, and median age at me-
narche between female offspring of the study group of
this birth cohort that participated in the 18 year exam
(n = 660) and those who were randomly selected for the
DNA-M analysis (n = 245; Table 1). However, OCP miss-
ingness was different between the study group at 18 years
and the 245 randomly selected girls. The difference is re-
lated to more missing information in the female study
group at 18 years (n = 32, 4.9%) compared to the random
selection of 245 with blood samples (n = 2, 0.8%). Ignoring
Table 1 Characteristics of subjects with available methylation data compared to the female participants of the total
cohort
Total female participants,
n (%)
Female participants with DNA-M data,
n (%)
P value
Factors n = 660 n = 245
Maternal smoking during pregnancy
Yes 159 (24.1) 47 (19.2)
No 498 (75.5) 197 (80.4) 0.29
Missing 7 1 (0.41)
Maternal history of asthma
Yes 67 (10.2) 30 (12.2)
No 588 (89.1) 213 (86.9) 0.66
Missing 5 (0.8) 2 (0.82)
Asthma at 18 years
Yes 128 (19.4) 35 (14.3)
No 531 (80.5) 210 (85.7) 0.17
Missing 1 (0.2) 0
Oral contraceptive use at 18 years
Yes 293 (44.4) 117 (47.8)
No 335 (50.7) 126 (51.4) 0.02
Missing 32 (4.9) 2 (0.8)
Smoking at 18 years
Yes 192 (29.1) 63 (25.7)
No 455 (68.9) 181(73.9) 0.13
Missing 13 (2.0) 1 (0.4)
Socioeconomic status
High 49 (7.4) 22 (9.0)
Medium 479 (72.6) 182 (74.3) 0.69
Low 94 (14.2) 37 (15.1)
Missing 38 (5.8) 4 (5.8)
n (Median; 5%, 95%) n (Median; 5%, 95%)
Body mass index at 10 years (kg/m2) 527 (17.9;14.8, 25.2) 223 (17.9;15.04, 25.3) 0.92
Missing 223 22
Body mass index at 18 years (kg/m2) 499 (22.2;18.2, 32) 240 (22.9;19.05, 32.93) 0.56
Missing 251 5
Age at menarche 631 (13.0;11.0,15.0) 233 (13.0;10.0, 15.0) 0.32
Missing 119 12
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(P = 0.75). The reason for the missingness seems to
be parental control at 18 years. In general, partici-
pants were interviewed separately in the study center;
however, they could also mail the questionnaire or an-
swer some questions on the phone. Fifteen of 16 girls with
a mailed questionnaire did not answer the question on
OCP use.
Among the female participants with methylation data,
12.2% had maternal history of asthma, 19.2% had mothersthat smoked during pregnancy, 14.3% had asthma at
18 years, 47.8% used OCPs at 18 years (44.4% of the girls
in the study group at the 18-year exam). The median age
at menarche was found to be 13 years. Use of oral contra-
ceptives and age at menarche in our sample are associated
(Wilcoxon test: P = 0.001); 62% of the participants with
age at menarche ≤11 years, 45.8% of those between 12
and 14 years, and 36% of those with ≥14 years used OCPs.
Of the thirteen GATA3 SNPs that were genotyped,
seven SNPs (rs1269486, rs3802604, rs3824662, rs422628,
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further analysis since these were uncorrelated (Figure 1).
Of the seven SNPs that were analyzed, rs1269486 was lo-
cated in the promoter, followed by four SNPs (rs3802604,
rs3824662, rs422628, and rs406103) in introns, and two
SNPs (rs434645, and rs12412241) downstream of the
GATA3 gene (Table 2). The mean methylation levels
(β value) of six of the 14 CpG sites of the GATA3 gene
were low (<0.10; Table 3), four were highly methylated
(>0.90), while four CpG sites showed wider variation in
methylation between individuals with mean methylation
between >0.10 and <0.55.
In stage 1, after controlling for cell type compos-
ition in peripheral blood, the interaction term ‘OCP
use × rs1269486’ was found to be associated with dif-
ferential methylation of cg17124583 (P value = 0.002;
FDR P value = 0.04; Table 4), indicating that this SNP
represents a conditional methQTL. OCP users with minor
allele (AA) (the difference in a logit scale is -0.86;
P value = 0.03) and heterozygous (AG) (the difference in
a logit scale is -0.57; P value = 0.002) genotypes for
rs1269486 had lower average methylation than those
with the major (GG) genotype. The association was ad-
justed for potential confounders including socioeconomic
status, smoking at 18 years, and BMI at 18 years. However,
none of these potential confounders changed the inter-
action effect by more than 10%.
To replicate the OCP usage model with an alternate
indicator for endocrine effects, age at menarche was in-
vestigated (Table 4). Indeed, methylation of cg17124583Figure 1 Linkage disequilibrium of GATA3 single nucleotide polymorpwas differentially methylated by the interaction of same
SNP rs1269486 and age at menarche (P = 0.0017). In
girls with the minor and heterozygous genotypes for
rs1269486 methylation levels at cg17124583 were found
to be higher if age at menarche was higher. The inter-
action was statistically significant only in those with the
minor genotype (the difference in logit scale is 0.42;
P value = 0.003). Hence, both OCP use and age at menar-
che in interaction with rs1269486 were associated with
differential methylation of cg17124583.
Interestingly, in a small sample of 34 paired DNA-M
measurements, the differentially methylated CpG site
cg17124583 show some variability from 10 to 18 years
(test for stability: ICC = 0.39, P = 0.01) with mean methy-
lation levels of 0.06 and 0.05, respectively. This CpG site
shows both stability and variability, but its variance was
not explained by OCP use or by age at menarche (data
not shown).
In the second stage, we analyzed whether methylation of
cg17124583 modifies the association between SNPs and
asthma at 18 years. We tested the interaction between
seven SNPs and the methylation levels of cg17124583 (dif-
ferentially methylated in stage 1), and its association with
asthma at 18 years. We found statistically significant inter-
actions between the SNPs rs434645 and rs422628 with
cg17124583 that modify the risk of asthma at 18 years
(Table 5). For rs434645, the minor (AA) and heterozygous
(AG) genotypes were combined since the direction of ef-
fect on methylation was the same for both. Then the stat-
istical association of the interaction of cg1712583 andhisms, standard (D’/LOD) color scheme; D’ LD values displayed.
Table 2 Single nucleotide polymorphisms (SNPs) for
GATA3 and their genotypes
SNP Positiona Location Genotype Frequency
n (%)
rs1269486 8096199 Promoter AA 13 (5.7)
AG 87 (37.8)
GG 130 (56.5)
rs3802604 8102272 Intron AA 88 (38.4)
AG 103 (45.0)
GG 130 (56.5)
rs3824662 8104208 Intron AA 8 (3.4)
AC 69 (29.6)
CC 156 (67.0)
rs422628 8111409 Intron GG 12 (5.1)
AG 93 (39.9)
AA 128 (55.0)
rs406103 8111621 Intron (boundary) AA 13 (5.6)
AG 78 (33.5)
GG 142 (60.9)
rs434645 8121451 3’UTR AA 4 (1.7)
AG 67 (29.3)
GG 158 (69.0)
rs12412241 8127139 Downstream AA 19 (8.1)
AG 92 (39.7)
GG 121 (52.1)
aNucleotide position on chromosome 10 based on build GRCh37.p13.
Table 3 Distribution of methylation on CpG sites of GATA3 ge
CpG site Location Position
cg18599069 5'UTR 8096991
cg10008757 5'UTR 8097183
cg14327531 5'UTR 8097331
cg17124583 Body 8097641
cg19883813a Body 8098005
cg11430077 Body 8099018
cg01255894 Body 8099218
cg10089865 Body 8100286
cg22770911 Body 8101307
cg04492228 Body 8101513
cg17489908 Body 8101566
cg03669298 Body 8102210
cg00463367 Body 8103673
cg04213746 Body 8106003
cg27409129 Body 8111731
cg07989490b 3'UTR 8117026
aCpG site is not considered for further analysis because of a low methylation level (
bCpG site is not considered for further analysis because of a probe SNP.
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checked using the common genotype (GG) as the refer-
ence. The interaction was found to be significant (P =
0.01; Table 5), however, it did not survive multiple testing
with FDR. For the SNP rs422628, an additive genetic
model was used to compare participants who had the
minor (GG) and heterozygous (AG) genotypes, with those
who have common (AA) genotype. The interaction term
‘cg17124583 × rs422628’ was found to be statistically
significantly associated with asthma in those with the
heterozygous genotype after adjusting for multiple com-
parisons (P = 0.006; FDR adjusted P = 0.05; Table 5). The
consecutive flow of assessments and its results is outlined
in Figure 2. The range of DNA-M for cg17124583 was
0.01 to 0.46. Since the number of participants at methyla-
tion levels of <0.02 and >0.14 were low, we grouped lower
methylation levels into ≤0.02 (n = 4) and larger into ≥0.14
(n = 9). Descriptively, 157 participants had average methy-
lation levels of 0.05 and less at this CpG, 71 participants
had 0.06 to 0.09, and 17 participants had 0.10 to 0.46. For
subjects with AG and GG genotypes, we examined the
RRs for asthma at different levels of DNA methylation.
Here we present RRs for the AG genotype for the follow-
ing levels: 0.02, 0.04, 0.06, 0.08, 0.10, and 0.12 relative to
subjects with AA genotype. For the AG genotype, the cor-
responding RRs of asthma are 0.31, 0.63, 1.31, 2.71, 5.62,
and 11.65 (Figure 3). The respective 95% CI are found in
the legend of Figure 3. Figure 3 shows that the relative risk
(RR) for the rs422628 AG genotype relative to AA was
higher when cg17124583 was more methylated.ne
Mean methylation 5% value 95% value
0.06 0.04 0.07
0.07 0.05 0.09
0.06 0.04 0.08
0.05 0.02 0.10
0.04 0.02 0.08
0.11 0.05 0.20
0.06 0.03 0.09
0.93 0.91 0.95
0.52 0.44 0.60
0.19 0.13 0.26
0.25 0.17 0.34
0.06 0.04 0.09
0.20 0.11 0.31
0.95 0.93 0.96
0.93 0.92 0.94
0.95 0.94 0.97
<5%).
Table 4 Assessment of interaction of single nucleotide polymorphisms with oral contraceptive use, and with age at
menarche on the methylation of the CpG site cg17124583 using linear regressiona
Parameter Estimate (Standard error) P value
Not adjusted for cell type Adjusted for cell type Not adjusted for cell type Adjusted for cell typea
OCP use 0.12 (0.11) 0.16 (0.11) 0.28 0.16
rs1269486 AA 0.64 (0.24) 0.68 (0.25) 0.009 0.006
AG 0.41 (0.12) 042 (0.13) 0.001 0.001
GG Reference
OCP use × rs1269486 AA -0.72 (0.39) -0.86 (0.40) 0.06 0.03
AG -0.55 (0.18) -0.57 (0.18) 0.002 0.002
GG Reference
Age at menarche -0.09 (0.04) -0.09 (0.04) 0.05 0.06
rs1269486 AA -5.28 (1.77) -4.87 (1.78) 0.003 0.006
AG -1.12 (0.86) -1.06 (0.86) 0.19 0.21
GG Reference
Age at menarche × rs1269486 AA 0.45 (0.14) 0.42 (0.14) 0.001 0.003
AG 0.09 (0.06) 0.09 (0.06) 0.14 0.16
GG Reference
aAdjusted for socioeconomic status, smoking at 18 years, BMI at 18 years, and cell mixture of the peripheral blood using the Houseman formula [41].
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Of the 14 CpGs and the seven SNPs that were analyzed,
we identified a conditional methQTL (rs1269486) inter-
acting with OCP usage and with age at menarche lead-
ing to a differential DNA-M of cg17124583 (Figure 2).
The same differentially methylated CpG site cg17124583
in interaction with another SNP rs422628 (modGV) was
found to modify the association of asthma at 18 years.
This association remained statistically significant afterTable 5 Log-linear models of interaction between genetic var
cg17124583 in the GATA3 gene on the prevalence of asthma
Single nucleotide and CpG site Genotype Es
Model for rs434645:
cg17124583 -2
rs434645 AA and AG -1
GG Re
cg17124583 × rs434645 AA and AG 32
GG Re
Model for rs422628:
rs422628 GG -0
AG -1
AA Re
cg17124583 × rs422628 GG -8
AG 36
AA Re
aAdjusted for socioeconomic status, maternal smoking during pregnancy, smoking
bThe estimate needs to be exponentiated to calculate the risk ratio. In addition, to
effects and the interaction effect into account. The information is provided in Figuradjusting for multiple comparisons using FDR. To our
knowledge, this is the first study to identify those SNPs
in the GATA3 gene that in interaction with OCP use,
and with age at menarche, are associated with differen-
tial methylation of GATA3 CpG sites and consecutively
with asthma.
Although the CpG site cg17124583 is located 13,768
base pairs away from rs422628, we can see that the risk
of asthma is modulated by this CpG site. It is possibleiants (rs434645 and rs422628) with DNA methylation of
at 18 yearsa
timateb (log RR) 95% CI of log RR P value
0.31
.19 -2.61, 0.23 0.10
ference
.77 7.36, 58.17 0.01
ference
.35 -3.58, 2.89 0.83
.91 -3.41, -0.41 0.01
ference
.62 -71.11, 53.86 0.79
.41 10.67, 62.14 0.006
ference
at age 18, and BMI at age 18.
estimate the risk ratio due to the interaction, we need to take the two main
e 3.
Figure 2 Consecutive assessments of stage 1 (conditional
methylation quantitative trail locus) and stage 2 (modifiable
genetic variant) assessments.
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genetic variant, which is responsible for the functional
effect on asthma risk and is adjacent to cg17124583, as
has been previously observed for another gene [32].
The probability of a selection bias seems to be negli-
gible as the study participants were randomly selected
for the DNA-M analysis and for all but one variable
there were no significant differences between the study
population and the cohort girls who participated at
18 years. However, the proportion of missing informa-
tion about the use of oral contraceptives at 18 years of
age was higher in female cohort members. This was
likely due to parental control, since nearly all girls whoseLegend
The blue bars present the relative frequency of the
methylation is found in 28% of the participants. Th
horizontal line that indicates a risk ratio value of 1
and the diamond is the GG genotype.
Methylation 
level (%) 0.02 0.03 0.04 0.05 0.06
95% CI of the 
risk ratio for AG
0.10-
0.89
0.18-
1.09
0.29-
1.38
0.44-
1.89
0.61
2.82
Figure 3 Risk ratio of asthma at 18 years versus methylation at differ
AA [reference].questionnaire was mailed had missing information. We
do not consider that the bias of parental control biases
our results.
As the information on the use of OCPs is self-reported
by the participants, there is a possibility of a misclassifi-
cation. However, previous studies have shown high
agreement between questionnaire data and medical re-
cords for any OCP use, current use, and time since first
use [33,34]. In addition, since age at menarche is an im-
portant event in a women’s life, thus, misclassifications
are unlikely [35]. As the women were neither aware of
their SNPs nor the methylation status, any recall bias
would result in a non-differential misclassification and
likely underestimate the true association. We repeated
the analyses with a different exposure marker for endo-
crine effects, namely age at menarche, which showed a
similar result. It therefore seems highly likely that the
significant effects we observe on asthma risk represent
an authentic link to endocrine events via differential
methylation of the GATA3 gene.
The DNA-M in our study was obtained using the Illumina
Infinium HumanMethylation450 beadchip array, which is
demonstrated to have high validity and high reproducibil-
ity [36]. As DNA-M can be tissue-specific, it is also DNA methylation levels. For instance, 4% 
e reference genotype is AA, which is a solid 
. The black dot represents the AG genotype, 
0.07 0.08 0.09 0.10 0.11 0.12
- 0.78-
4.54
0.96-
7.71
1.13-
13.52
1.31-
24.16
1.5-
44.66
1.71-
79.5
ent genotypes of GATA3 rs422628: AG and GG compared to
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peripheral blood represented methylation profiles in other
tissues. This issue is currently under debate [37-40]. In
addition, peripheral blood leukocytes represent a mixture
of cells [41]. Using CpG site information, we estimated
the relative contribution of cell type composition in per-
ipheral blood using the Houseman approach [41]. The es-
timated cell type composition had only a minor influence
on the DNA-M of GATA3 CpG sites (Table 4), suggesting
that differences in the proportions of different leukocyte
do not underlie the effects reported here.
In the regression models, we observed that, although the
main effects of OCP use, age at menarche, and SNPs were
not significantly associated with DNA-M of cg17124583,
their interactions were found to be significantly associated
even after penalizing for multiple testing. Similarly, no
main effects were seen for the association of OCP use,
cg17124583, and the SNPs on the risk for asthma at
18 years. However, the interaction of the SNP and DNA-M
were found to be statistically significant. The importance
of genome-epigenome interactions in disease is increas-
ingly recognized [42]. For example, DNA-M at the IL4R
locus interacts with a local SNP to increase the RR of
asthma much more dramatically than does either geno-
type or methylation alone [43]. Likewise DNA-M and
genotype at the IL13 locus interact to influence lung func-
tion [44]. It is therefore of great importance to consider
not only the disease risk imparted by the genome se-
quence, but how this is modified by DNA-M, which itself
by be affected by environmental exposures.
Asthma being considered mainly a ‘Th2 disease’, we
focused on the GATA3 gene because it is known to be
the master regulator of Th2 cell differentiation [19] and
has been linked to endocrine responses [45]. Estrogen is
an immune modulator and is known to stimulate the
production of Th2 cytokines, which include IL-4, IL-5,
and IL-13 [11,13]. Our findings show that OCP use
modifies the DNA-M of GATA3 gene. We speculate that
OCPs, which contain estrogen and progesterone [46,47],
may influence Th2 cytokine production via the differen-
tial methylation of GATA3 gene. Similar findings are
seen with age at menarche altering the DNA-M of GATA3
gene. Statistically, although early age at menarche is re-
lated to use of OCPs, the two variables are not in
complete agreement and seem to measure different fea-
tures. Age at menarche is related to endogenous sex hor-
mones [48], whereas OCPs are exogenous sex hormones.
We believe that the agreement of our stage 1 findings be-
tween OCP use and age at menarche provides credence to
our results. Our two-stage model suggests a potential
pathway in which sex hormone-related exposures such as
OCP use and age at menarche alter the DNA-M within
GATA3 to subsequently affect the risk for asthma in girls
at 18 years. We believe that using the two-stage modelprevents reverse associations, namely that asthma initiates
changes of CpG sites. In the first stage, cg17124583 was
the only CpG site selected due to its relation with the
interaction term of OCP use with one genetic variant
(rs1269486) of the GATA3 gene and corroborated with
age at menarche. Then only this CpG site was tested for
an association with asthma at 18 years. However, it is not
likely, but still possible that three variables (oral contra-
ceptive use, asthma, and rs1269486) interacted in concert
to influence the methylation of cg17124583.
A limitation of our study is that the RRs at methyla-
tion levels larger than 9% are only based on a limited
number of individuals (n = 17). Another limitation is the
lack of availability of the information on the type of
OCP (estrogen/progesterone only pills or a combined
pill), and length of time on the OCP which can further
help to elucidate the role of either estrogen/progesterone
or both in DNA methylation, genetic polymorphisms,
and asthma.
Conclusions
This study represents the first report of an interaction of
genetic variation and DNA-M of GATA3 on the risk for
asthma at 18 years, which is modified by the use of OCP
and age at menarche. The findings suggest a potential
pathway in which OCP exposure and age at menarche,
presumably via sex hormones, can alter the DNA-M of a
GATA3 CpG site, which subsequently, in conjunction
with genetic variants, influences the risk of asthma at
18 years. These findings provide a possible explanation
for the increase in asthma prevalence in girls/women
after puberty. Our results should motivate other re-
searchers to search for interactions between genetic vari-
ants, sex hormones, and DNA-M.
Methods
Study design and population
A whole population birth cohort was established in the
Isle of Wight, UK in 1989 to prospectively study the nat-
ural history and etiology of asthma and allergic conditions.
The local research ethics committee (NRES Committee
South Central - Hampshire B) approved the study and
written informed consent was obtained from 1,456 chil-
dren (January 1989 to February 1990), who were followed
up at 1, 2, 4, 10, and 18 years. This Caucasian birth cohort
has been described in detail elsewhere [49]. Question-
naires were completed for each child at every follow-up.
Blood or saliva samples were collected at the ages of 10
and 18 years for genetic analysis.
Exposures
Information on OCP use was collected at 18 years. The
question was: ‘Are you on the contraceptive pill?’ Age at
menarche was assessed using the National Institute of
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from the Study of Early Child Care and Youth Develop-
ment, which is based on the Pubertal Development Scale
(PDS) method [50]. Among other questions on pubertal
signs, the questionnaire asked: ‘How old were you when
you started to menstruate?’
Outcome
Asthma information was collected using the International
Study of Asthma and Allergies in Childhood (ISAAC)
questionnaire [51]. The questions for assessing asthma
were as follows: ‘History of physician diagnosed asthma?’,
‘Wheezing or whistling in the chest in the last 12 months?’
and ‘Asthma treatment in the last 12 months?’ Based on
the answers to these questions, asthma at 18 years was de-
fined by physician diagnosis of asthma plus current symp-
toms and/or currently on asthma medication.
Genotyping
Genomic DNA was isolated from blood samples by
using QIAamp DNA Blood Kits (Qiagen, Valencia, CA,
USA) or the ABI PRISM 6100 Nucleic Acid PrepStation
(Applied Biosystems, Foster City, CA, USA). In some
cases genomic DNA was isolated from saliva using Oragene
DNA Self Collection Kits (DNA Genotek, Ottawa, ON,
Canada). Polymorphisms in the GATA3 gene were exam-
ined using the SNPper and Applied Biosystems databases.
Genotyping was conducted by fluorogenic 5’ nuclease
chemistry PCR using Assays on Demands kits cycled on a
7900HT Sequence Detection System (Applied Biosystems,
Foster City, CA, USA), or biotin-streptavidin-based pyro-
sequencing performed on PSQ-6 instrumentation (Biotage
AB, Uppsala, Sweden). SNPs (n = 17) that tagged the
GATA3 gene were identified using a tagger implemented
in Haploview 4.2 using Caucasian Hapmap data, including
10 kb upstream and downstream of the GATA3 gene [52].
Estimates of linkage disequilibrium (LD) between SNPs
were calculated using D’ and r2. An r2 value of 0.85 was
the threshold for tagging, and seven SNPs were selected (1
SNP from each of the 5 haplotype blocks and 2 SNPs that
did not have strong linkage disequilibrium with other
SNPs, Figure 1).
DNA Methylation
Stored blood samples collected at 10 and 18 years were
available on the Isle of Wight, UK. For the measurement
of DNA methylation at 18 years in girls, the team in the
United States provided a list of 245 random identifica-
tion numbers to be selected from the samples on the Isle
of Wight, UK. Then for additional DNA methylation
analyses of samples when these 245 women were 10 years
of age, we randomly selected 34 blood samples with 16 girls
with asthma and 18 girls without. DNA methylation was
assessed using Illumina Infinium HumanMethylation450BeadChips (Illumina, Inc, SanDiego, CA, USA). The 18-
year samples were processed in one batch. In addition,
DNA methylation data were available for a sample of 34
girls at 10 years of age processed in another batch. DNA
from blood samples was extracted for methylation arraying
using a salting out procedure. One microgram of DNA was
bisulfite-treated for cytosine to thymine conversion using
the EZ 96-DNA methylation kit (Zymo Research, CA,
USA), following the manufacturer’s standard protocol.
Arrays were processed using a standard protocol as de-
scribed elsewhere [53]. The Bead Chips were scanned
using a Bead Station, and the methylation level (beta (β)
value) was calculated for each queried CpG locus using
Methylation module of GenomeStudio software.
Covariates
Maternal history of asthma and maternal smoking during
pregnancy was assessed by a questionnaire administered
after birth. Information about the child’s active smoking
status and body mass index (BMI) was collected from the
18-year questionnaire and anthropometric measurements
conducted at the age of 18 years. Also assessed was ‘family
social status cluster’, which is a composite variable derived
from a combination of family income, parental occupation
(socioeconomic status), and number of children in a child’s
bedroom [54].
In addition, since DNA methylation found in peripheral
blood cells depends on cell types, we adjusted all stage 1
models for cell mixture using the method proposed by
Houseman et al [41]. This method identifies CpGs within
differentially methylated regions known to distinguish six
types of white blood cells and then utilizes β values at
these CpGs to predict the proportions of CD8+ T-cells,
CD4+ T-cells, natural killer cells, B-cells, monocytes, and
granulocytes for each blood sample. The rationale to use
this method for stage 1 is to estimate the change in DNA-
M that is due to differential methylation but not due to a
change in peripheral blood cell. Once we have identified
such differential DNA-M, in stage 2 we are more inter-
ested in the concert of cells and their methylation level on
the outcome asthma.
Statistical analysis
Preprocessing of the DNA-M data was undertaken using
the IMA [55] package implemented in the R statistical
computing package [56]. To identify tag-SNPs, LD be-
tween SNPs was calculated using D’ and r2 [57] and they
were tested for Hardy-Weinberg equilibrium using Hap-
loview 3.2 software [52]. DNA-M levels were quantified
using β values that present the proportion of methylated
(M) over the sum of methylated and unmethylated (U)
allele intensities (β =M/[c +M +U]), with c being a con-
stant to prevent dividing by zero [58]. As the β value
method has severe heteroscedasticity, it is recommended
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tial methylation analysis [59]. A logit transformation was
employed for all β values to normalize their distribution.
To assess whether the subset population (n = 245) repre-
sents the total cohort of girls at 18 years, χ2 tests were
used.
In this study, 16 CpG sites that spanned the GATA3
gene were analyzed, out of which one CpG site was re-
moved due to the presence of a probe SNP. A probe
SNP is a single nucleotide polymorphism in the probe of
50 base-pairs used to determine the location of methyl-
ated CpG site. A SNP in the 50 base-pair probe may
interfere with the DNA-M measurement. A second CpG
site had an average methylation level <0.05, we removed
this site from analysis as CpGs that are either very highly
(>0.95) or very lowly (<0.05) methylated have too little
variance that can be explained statistically. We added ana-
lyses on whether chip and positions had an influence on
the M-values in the 245 samples. Neither chip nor posi-
tions showed significant effects or any substantial changes.
In addition, in 34 female participants stability of DNA-M
in blood between 10 and 18 years was estimated using
intraclass correlation coefficients (ICCs).
The aim of the first stage of the two-stage model was to
detect CpG sites that were affected by an interaction of
SNPs and OCP usage. We ran linear regression models, in
which each of the 14 CpG sites were modeled against
seven SNPs, each interacting with OCP use. Since we per-
formed 98 tests (14 × 7) we adjusted for multiple testing
by controlling the overall false discovery rate (FDR; overall
FDR = 0.05) [60].
Focusing on the CpG sites with significant interactions
with OCPs, we then reran the analyses of stage 1 using
age at menarche as exposure to determine if similar
associations occurred with this marker of endocrine
changes. If statistically significant associations are ob-
served for both sex hormone exposures, then this
strengthens the evidence that the association is related to
sex hormones.
In the second stage model with asthma as the dependent
variable, we used log-linear models (GENMOD procedure
in SAS 9.3) to estimate statistical interactions between
the methylation levels of CpG sites selected in stage 1
and GATA3 SNPs on the risk for asthma at age 18 years.
These models included the following potential con-
founders: maternal history of asthma, maternal smoking
during pregnancy, BMI at 18 years, smoking at 18 years,
and socioeconomic status. Those confounders that chan-
ged the association of interest by 10% or more were
retained as confounders in the final model. All hypotheses
tested were corrected for multiple testing using the FDR.
The statistical analyses were performed using the SAS
statistical package (version 9.3; SAS Institute, Cary, NC,
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